2023 Annual Meeting | S44 - Epilepsy/Clinical Neurophysiology (EEG): Epilepsy Outcomes
Program Materials Program Evaluations
| Cornelia Drees, MD | Dr. Drees has nothing to disclose. |
| Cynthia L. Harden, MD | Dr. Harden has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc.. Dr. Harden has stock in Xenon Pharmaceuticals Inc.. |
| Manisha Gupte Holmes, MD | Dr. Holmes has nothing to disclose. |
| Simona Vasilica Proteasa, MD | Dr. Proteasa has nothing to disclose. |
| Berten Ceulemans | The institution of Berten Ceulemans has received personal compensation in the range of $500-$4,999 for serving as a Consultant for zogenix. The institution of Berten Ceulemans has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for zogenix. Berten Ceulemans has received intellectual property interests from a discovery or technology relating to health care. |
| Selim R. Benbadis, MD, FAAN | Dr. Benbadis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stratus. Dr. Benbadis has received personal compensation in the range of $0-$499 for serving as a Consultant for Ceribell. Dr. Benbadis has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for SK Lifesciences. Dr. Benbadis has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Jazz. Dr. Benbadis has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eisai. Dr. Benbadis has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Neurelis. Dr. Benbadis has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sunovion. Dr. Benbadis has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Livanova. Dr. Benbadis has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Benbadis has received research support from Greenwich/Jazz. The institution of Dr. Benbadis has received research support from SK Lifesciences. |
| Blake Newman, MD | Dr. Newman has nothing to disclose. |
| Morgane Wartel, PhD | Dr. Wartel has received personal compensation for serving as an employee of uniQure biopharma B.V.. Dr. Wartel has stock in uniQure biopharma B.V.. |
| Annie Yang, MD | Dr. Yang has nothing to disclose. |
| Jacqueline French, MD, FAAN | The institution of Dr. French has received research support from Epilepsy Study Consortium/ Epilepsy Foundation (Funded by UCB). The institution of Dr. French has received research support from GW/One8 Foundation/FACES. The institution of Dr. French has received research support from NINDS. The institution of Dr. French has received research support from Xenon. The institution of Dr. French has received research support from Cerevel. The institution of Dr. French has received research support from FACES. The institution of Dr. French has received research support from UCB. The institution of Dr. French has received research support from Epilepsy Study Consortium. The institution of Dr. French has received research support from UCB. Dr. French has received personal compensation in the range of $100,000-$499,999 for serving as a Chief Medical/Innovation Officer with Epilepsy Foundation. Dr. French has a non-compensated relationship as a Consultant with Aeovian that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Alterity Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Anavex that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Arkin Holdings that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Athenen Therapeutics/Carnot Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Autifony Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Baergic Bio that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Biogen that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Biohaven Pharmaceuticals that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with BioMarin Pharmaceutical Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with BioXcel Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Bloom Science Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with BridgeBio Pharma Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Camp4 Therapeutics Corporation that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cerebral Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cerevel that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a SAB with Clinical Education Alliance that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a SAB with Coda Biotherapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Corlieve Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Crossject that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Eisai, that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Eliem Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Encoded Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Engage Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Engrail that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Epalex that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a SAB with Epihunter that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a SAB with Epiminder that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Epitel Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Equilibre BioPharmaceuticals that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Greenwich Biosciences that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Grin Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with GW Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Janssen Pharmaceutica that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Jazz Pharmaceuticals that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Knopp Biosciences that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Lipocine that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with LivaNova that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Longboard Pharmaceuticals that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Lundbeck that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Marinus that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Mend Neuroscience that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Merck that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with NeuCyte Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Neumirna Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Neurocrine that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Neuroelectrics USA Corporation that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Neuropace that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with NxGen Medicine Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Ono Pharmaceutical Co that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Otsuka Pharmaceutical Development that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Ovid Therapeutics Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Paladin Labs Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Passage Bio that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Pfizer that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Praxis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with PureTech LTY Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Rafa Laboratories Ltd that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with SK Life Sciences that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Sofinnova that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Stoke that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Supernus that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Synergia Medica that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Takeda that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with UCB Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Ventus Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consulting, steering committee with Xenon that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Xeris that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Zogenix that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Zynerba that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Alterity that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Biomarin that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, speaker with Angelini that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory board with Receptor that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory board, consultant with Biohaven that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a advisory board, consultant with CAMP4 that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory board with Cognizance Biomarker that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Rapport Therapeutics, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory board with Sage Therpeutics that is relevant to AAN interests or activities. |
| Kelly G. Knupp, MD | Dr. Knupp has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for zogenix. Dr. Knupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for encoded. Dr. Knupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for stoke. The institution of Dr. Knupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW pharmaceuticals. Dr. Knupp has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsy Research. |
| Nick Pearson | No disclosure on file |
| Katherine C. Nickels, MD, FAAN | The institution of Dr. Nickels has received research support from Zogenix. The institution of Dr. Nickels has received research support from Marinus. The institution of Dr. Nickels has received research support from Bio-Pharm Solutions. The institution of Dr. Nickels has received research support from Pediatric Epilepsy Research Foundation. Dr. Nickels has received personal compensation in the range of $500-$4,999 for serving as a Faculty with J. Kiffin Penry Educational Programs. |
| Catherine Riney | No disclosure on file |
| Mei Jiang, PhD | Dr. Jiang has received personal compensation for serving as an employee of LivaNova Inc. Dr. Jiang has stock in LivaNova. |
| Wesley Kerr, MD, PhD | The institution of Dr. Kerr has received research support from NIH. Dr. Kerr has received publishing royalties from a publication relating to health care. |
| Antonio Gil-Nagel, MD | Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EISAI . Dr. Gil-Nagel has received personal compensation in the range of $0-$499 for serving as a Consultant for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Angelini Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoke . Dr. Gil-Nagel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zogenix . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIAL . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EISAI . Dr. Gil-Nagel has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PTC Therapeutics . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zogenix . The institution of Dr. Gil-Nagel has received research support from Jazz Pharmaceuticals. The institution of Dr. Gil-Nagel has received research support from PTC Therapeutics. The institution of Dr. Gil-Nagel has received research support from Zogenix. The institution of Dr. Gil-Nagel has received research support from Agencia Estatal Innovacion. |
| William E. Rosenfeld, MD, FAAN | The institution of Dr. Rosenfeld has received personal compensation in the range of $500,000-$999,999 for serving as a Consultant for SK Life Science. Dr. Rosenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for SK Life Science. |
| Amelie Lothe, PhD | Dr. Lothe has received personal compensation for serving as an employee of UCB. Dr. Lothe has received personal compensation for serving as an employee of Zogenix International Limited. Dr. Lothe has stock in Zogenix . |
| Mahnaz Asgharnejad, PharmD | Mahnaz Asgharnejad, PharmD has received personal compensation for serving as an employee of Takeda Pharmaceuticals. Mahnaz Asgharnejad, PharmD has stock in GlaxoSmithKline. Mahnaz Asgharnejad, PharmD has stock in Takeda Pharmaceuticals. |
| Muhammad Shahzad Zafar, MBBS | Dr. Zafar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Xenon Pharmaceuticals. Dr. Zafar has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for LivaNova . The institution of Dr. Zafar has received research support from UCB. The institution of Dr. Zafar has received research support from SK life. The institution of Dr. Zafar has received research support from Marinus. The institution of Dr. Zafar has received research support from LivaNova. The institution of Dr. Zafar has received research support from Biopharma. The institution of Dr. Zafar has received research support from Neurocrine. The institution of Dr. Zafar has received research support from Hartwell Foundation. |
| Anuja R. Patil, MD, DM | Dr. Patil has nothing to disclose. |
| Andreas Borta, MD,PhD | Dr. Borta has received personal compensation for serving as an employee of uniQure. Dr. Borta has stock in uniQure. |
| Naga Venkatesha Murthy Pathi Jagannatham, MD | Dr. Pathi Jagannatham has received personal compensation for serving as an employee of Takeda Pharmaceuticals. Dr. Pathi Jagannatham has received personal compensation for serving as an employee of GlaxoSmithKline. Dr. Pathi Jagannatham has stock in Takeda Pharmaceuticals. Dr. Pathi Jagannatham has stock in GlaxoSmithKline. |
| Krista Proteasa | Miss Proteasa has nothing to disclose. |
| Ingrid E. Scheffer, AO, MBBS, PhD, FRACP | Dr. Scheffer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Xenon Pharmaceuticals. Dr. Scheffer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Zynerba Pharmaceuticals. Dr. Scheffer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Atheneum Partners. Dr. Scheffer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BioMarin. The institution of Dr. Scheffer has received research support from National Health and Medical Research Council, Australia. The institution of Dr. Scheffer has received research support from National Health and Medical Research Council, Australia. The institution of Dr. Scheffer has received research support from National Health and Medical Research Council, Australia. The institution of Dr. Scheffer has received research support from National Health and Medical Research Council, Australia. The institution of Dr. Scheffer has received research support from National Health and Medical Research Council, Australia. The institution of Dr. Scheffer has received research support from National Health and Medical Research Council, Australia. The institution of Dr. Scheffer has received research support from Medical Research Future Fund, Australia. The institution of Dr. Scheffer has received research support from Medical Research Future Fund, Australia. The institution of Dr. Scheffer has received research support from Shenzhen Sanming Development Grant . Dr. Scheffer has received intellectual property interests from a discovery or technology relating to health care. Dr. Scheffer has received intellectual property interests from a discovery or technology relating to health care. Dr. Scheffer has received intellectual property interests from a discovery or technology relating to health care. Dr. Scheffer has received personal compensation in the range of $500-$4,999 for serving as a Travel/Conference/Speaker honoraria with BioMarin. Dr. Scheffer has received personal compensation in the range of $500-$4,999 for serving as a Travel/Conference/Speaker honoraria with UCB. Dr. Scheffer has received personal compensation in the range of $500-$4,999 for serving as a Travel/Conference/Speaker honoraria with Eisai. Dr. Scheffer has a non-compensated relationship as a Scientific Advisory Board, Trial Investigator with UCB that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with Eisai that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Scientific Advisory Board with Rogcon that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Scientific Advisory Board, Trial investigator with Zynerba Pharmaceuticals that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Scientific Advisory Board with Chiesi that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Scientific Advisory Board, Trial investigator with Encoded Therapeutics that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Journal Editorial Board with Neurology that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Journal Editorial Board with Epilepsy Currents that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Journal Editorial Board with Epileptic Disorders that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with Ovid Therapeutics that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Consultant with Atheneum Partners that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with GW Pharmaceuticals that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with Marinus that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with Zogenix that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with Ultragenyx that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with Anavex Life Sciences that is relevant to AAN interests or activities. |
| Sonay Keskin | Mr. Keskin has received personal compensation for serving as an employee of uniQure. Mr. Keskin has stock in uniQure. Mr. Keskin has a non-compensated relationship as a Technician with uniQure that is relevant to AAN interests or activities. |
| Roger J. Porter, MD, FAAN | Dr. Porter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Otsuka. Dr. Porter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cadent. Dr. Porter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Xenon. Dr. Porter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Aeterna. Dr. Porter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Passage Bio. Dr. Porter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Porter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Longboard. Dr. Porter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Engrail. Dr. Porter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Xenon. Dr. Porter has received publishing royalties from a publication relating to health care. Dr. Porter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with Epilepsy Study Consortium. |
| Rima Nabbout | No disclosure on file |
| Michael A. Rogawski, MD, PhD | Dr. Rogawski has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Xenon Pharmaceuticals. |
| Christophe Mulle, PhD | Dr. Mulle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Corlieve Therapeutics. Dr. Mulle has stock in Corlieve Therapeutics. |
| Lakshmi Priya | Dr. Priya has nothing to disclose. |
| Michael P. Macken, MD,MRCPI | Dr. Macken has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharma. Dr. Macken has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK LifeSciences. Dr. Macken has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for LivaNova. Dr. Macken has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Hall Prangle Shonfeld. The institution of Dr. Macken has received research support from LivaNova. |
| Jenny Qian | Ms. Qian has received personal compensation for serving as an employee of Xenon Pharmaceuticals. |
| Lesley Kaye, MD | The institution of Dr. Kaye has received research support from NeuroPace. The institution of Dr. Kaye has received research support from LivaNova. |
| Ashalatha Radhakrishnan, Sr., MD | Dr. Radhakrishnan has nothing to disclose. |
| Sita Jayalakshmi Sattaluri | Dr. Sattaluri has nothing to disclose. |
| Sarah Barnard | Sarah Barnard has nothing to disclose. |
| Danielle S. McDermott, MD | The institution of Dr. McDermott has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Marinus Pharmaceuticals . Dr. McDermott has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK biosciences . |
| Pegah Afra, MD, FAAN | The institution of Dr. Afra has received research support from LivaNova and UCB. Dr. Afra has a non-compensated relationship as a board member (representing AAN) with CoA-NDT that is relevant to AAN interests or activities. |
| Mesha Gay Brown, MD | Dr. Brown has nothing to disclose. |
| Rebecca O'Dwyer, MD | Dr. O'Dwyer has nothing to disclose. |
| Constanza Luzon | Constanza Luzon has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc.. Constanza Luzon has stock in Xenon Pharmaceuticals. |
| Pranab K. Mitra, PhD | Dr. MITRA has nothing to disclose. |
| Sean Stern | Mr. Stern has received personal compensation for serving as an employee of SK Life Science. |
| Robert T. Wechsler, MD, PhD, FAAN | The institution of Dr. Wechsler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Otsuka. The institution of Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. The institution of Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Life Science. The institution of Dr. Wechsler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Aquestive. The institution of Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Engage. The institution of Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Greenwich. The institution of Dr. Wechsler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel. The institution of Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eisai. The institution of Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sunovion. The institution of Dr. Wechsler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eliem. The institution of Dr. Wechsler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. The institution of Dr. Wechsler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Epalex. The institution of Dr. Wechsler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Engrail. The institution of Dr. Wechsler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurona. Dr. Wechsler has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurelis. Dr. Wechsler has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Sunovion. Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB. Dr. Wechsler has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Greenwich. Dr. Wechsler has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Eisai. Dr. Wechsler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aquestive. Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for SK Life Science. Dr. Wechsler has a non-compensated relationship as a Board President with Epilepsy Foundation of Idaho that is relevant to AAN interests or activities. |
| Kristl Vonck, Jr., MD,PhD | Prof. Vonck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Livanova. Prof. Vonck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Synergia Medical. Prof. Vonck has received personal compensation in the range of $0-$499 for serving as a Consultant for All Man Foundation. Prof. Vonck has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Livanova. Prof. Vonck has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. The institution of Prof. Vonck has received research support from FWO. The institution of Prof. Vonck has received research support from GSKE. |
| William O. Tatum, IV, DO, FAAN | Dr. Tatum has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bioserenity. Dr. Tatum has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Natus. Dr. Tatum has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Tatum has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Tatum has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Defense Law Firm on behalf of a patient with epilepsy with funds donated to the Epilepsy Foundation of America. The institution of Dr. Tatum has received research support from Esai. The institution of Dr. Tatum has received research support from Mayo Clinic. The institution of Dr. Tatum has received research support from Liva Nova. The institution of Dr. Tatum has received research support from Engage Pharmaceuticals. The institution of Dr. Tatum has received research support from Xenon. Dr. Tatum has received intellectual property interests from a discovery or technology relating to health care. Dr. Tatum has received publishing royalties from a publication relating to health care. Dr. Tatum has received publishing royalties from a publication relating to health care. Dr. Tatum has received publishing royalties from a publication relating to health care. Dr. Tatum has a non-compensated relationship as a AAN Section Chair of Clinical Neurophysiology with AAN that is relevant to AAN interests or activities. |
| Clarence Wade | Mr. Wade has nothing to disclose. |
| Ronald G. Davis, MD | Dr. Davis has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for eisai. |
| Emilio Perucca | Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arvelle. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GW . Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi . Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Angelini. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zogenix. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shackelford. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SKB Life Sciences. The institution of Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Xenon. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Arvelle. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zogenix. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PMI Life Sciences. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Chiesi. Emilio Perucca has received publishing royalties from a publication relating to health care. Emilio Perucca has received publishing royalties from a publication relating to health care. Emilio Perucca has received publishing royalties from a publication relating to health care. |
| Ryan Verner | Ryan Verner has received personal compensation for serving as an employee of LivaNova USA Inc. Ryan Verner has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sella Therapies. Ryan Verner has stock in LivaNova PLC. |
| Dennis J. Dlugos, MD | Dr. Dlugos has received research support from NIH. The institution of Dr. Dlugos has received research support from The Epilepsy Study Consortium. |
| Shashank Jaiswal | Mr. Jaiswal has nothing to disclose. |
| David G. Vossler, MD, FAAN | Dr. Vossler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex Pharmaceuticals. Dr. Vossler has received personal compensation in the range of $0-$499 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Vossler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Longboard Pharmaceuticals. Dr. Vossler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Xenon Pharmaceuticals. Dr. Vossler has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK Life Science. The institution of Dr. Vossler has received research support from SK Life Science. The institution of Dr. Vossler has received research support from Xenon Pharmaceuticals. The institution of Dr. Vossler has received research support from Longboard Pharmaceuticals. |
| Gregory N. Beatch, PhD | Dr. Beatch has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc. Dr. Beatch has stock in Xenon Pharmaceuticals Inc. Dr. Beatch has received intellectual property interests from a discovery or technology relating to health care. |
| Amy Keith, Other | Ms. Keith has received personal compensation for serving as an employee of LivaNova USA, Inc.. Ms. Keith has stock in LivaNova USA, Inc.. |
| Shikha Polega | Shikha Polega has received personal compensation for serving as an employee of UCB. Shikha Polega has stock in UCB. Shikha Polega has stock in Zogenix. |
| Joseph Sullivan | Joseph Sullivan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epygenix. Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. The institution of Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Encoded Therapetucis. Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Invitate. Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Longboard. Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Greenwigh Biosciences. Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Knopp Biosciences. Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Asceneuron. Joseph Sullivan has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various Law Firms. Joseph Sullivan has received stock or an ownership interest from Epygenix Therapeutics. The institution of Joseph Sullivan has received research support from Zogenix. The institution of Joseph Sullivan has received research support from Marinus Pharmaceuticals. The institution of Joseph Sullivan has received research support from Stoke Therapeutics. The institution of Joseph Sullivan has received research support from Encoded Therapeutics. The institution of Joseph Sullivan has received research support from BioPharm solutions. |
| Yuan Yao, MD | Dr. Yao has received personal compensation for serving as an employee of Takeda Development Center. |
| Lieven G. Lagae, PhD | Dr. Lagae has nothing to disclose. |
| Christopher Kenney | No disclosure on file |
| Olivier Danos, PhD | Dr. Danos has received personal compensation for serving as an employee of REGENXBIO. Dr. Danos has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vor Bio. Dr. Danos has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Coave Therapeutics. Dr. Danos has stock in REGENXBIO. Dr. Danos has stock in Coave Therapeutics. Dr. Danos has stock in Rocket Therapeutics. |
| Renzo Guerrini | Renzo Guerrini has nothing to disclose. |
| Sameer M Zuberi, MD | Prof. Zuberi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Encoded Therapeutics. Prof. Zuberi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zogenix. Prof. Zuberi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GW Pharma. Prof. Zuberi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Prof. Zuberi has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Scottish Central Legal Office. Prof. Zuberi has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Balfour & Manson Solicitors. The institution of Prof. Zuberi has received research support from Epilepsy Research UK. The institution of Prof. Zuberi has received research support from Scottish Government Digital Health & Care. |
| Zeenat Jaisani, MD | Dr. Jaisani has nothing to disclose. |
| Nicolas Partouche, Other | Mr. Partouche has nothing to disclose. |
| Martin Brodie | Martin Brodie has nothing to disclose. |
| Valerie Crepel, PhD | Dr. CREPEL has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Corlieve Therapeutics. Dr. CREPEL has stock in Corlieve Therapeutics. The institution of Dr. CREPEL has received research support from Corlieve Therapeutics. Dr. CREPEL has received intellectual property interests from a discovery or technology relating to health care. |
| Richard Hugh Porter, PhD | Dr. Porter has received personal compensation for serving as an employee of Uniqure. Dr. Porter has stock in uniqure. Dr. Porter has stock in roche. |
| Stephane Baudouin, PhD | Dr. Baudouin has received personal compensation for serving as an employee of Uniqure. Dr. Baudouin has stock in Uniqure. |
| Anteneh Mekonnen Feyissa, MD, MSc, FAAN | Dr. Feyissa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. |
| Fred A. Lado, MD | Dr. Lado has a non-compensated relationship as a Board Member with American Epilepsy Society that is relevant to AAN interests or activities. Dr. Lado has a non-compensated relationship as a Officer with National Association of Epilepsy Centers that is relevant to AAN interests or activities. |
| Maria J. Bruzzone, MD | Dr. Bruzzone has nothing to disclose. |